ClinicalTrials.Veeva

Menu

Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor

Boehringer Ingelheim logo

Boehringer Ingelheim

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: ticagrelor
Drug: dabigatran etexilate

Study type

Interventional

Funder types

Industry

Identifiers

NCT01734772
1160.142
2012-002656-16 (EudraCT Number)

Details and patient eligibility

About

To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and ticagrelor under steady state conditions; to investigate the effect of staggered administration of ticagrelor loading dose on dabigatran exposure (in Part II)

Enrollment

48 patients

Sex

Male

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Healthy male subjects.

Exclusion criteria

  1. Any relevant deviation from healthy conditions.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

48 participants in 3 patient groups

Reference (Part 1/A, Part 2/C)
Experimental group
Description:
multiple doses of dabigatran (alone)
Treatment:
Drug: dabigatran etexilate
Drug: dabigatran etexilate
Drug: dabigatran etexilate
Test 1 (Part 1/Treatment B)
Experimental group
Description:
concomitant administration of dabigatran and ticagrelor
Treatment:
Drug: ticagrelor
Drug: dabigatran etexilate
Drug: dabigatran etexilate
Drug: ticagrelor
Drug: dabigatran etexilate
Drug: ticagrelor
Test 2 (Part 2/Treatment D)
Experimental group
Description:
staggered administration of ticagrelor and dabigatran
Treatment:
Drug: ticagrelor
Drug: dabigatran etexilate
Drug: dabigatran etexilate
Drug: ticagrelor
Drug: dabigatran etexilate
Drug: ticagrelor

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems